Ocular Therapeutix, Inc.
OCUL
$10.04
-$0.06-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 52.05M | 52.04M | 51.95M | 55.78M | 56.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.05M | 52.04M | 51.95M | 55.78M | 56.66M |
| Cost of Revenue | 230.22M | 227.09M | 203.67M | 193.50M | 177.98M |
| Gross Profit | -178.16M | -175.06M | -151.72M | -137.71M | -121.31M |
| SG&A Expenses | 135.74M | 124.38M | 118.30M | 113.72M | 107.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 365.96M | 351.48M | 321.97M | 307.22M | 285.40M |
| Operating Income | -313.91M | -299.44M | -270.02M | -251.43M | -228.73M |
| Income Before Tax | -301.45M | -290.50M | -265.94M | -249.67M | -216.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -301.45 | -290.50 | -265.94 | -249.67 | -216.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -301.45M | -290.50M | -265.94M | -249.67M | -216.75M |
| EBIT | -313.91M | -299.44M | -270.02M | -251.43M | -228.73M |
| EBITDA | -308.46M | -294.81M | -265.69M | -247.41M | -224.82M |
| EPS Basic | -1.41 | -1.46 | -1.44 | -1.44 | -1.28 |
| Normalized Basic EPS | -0.88 | -0.91 | -0.90 | -0.90 | -0.80 |
| EPS Diluted | -1.42 | -1.46 | -1.44 | -1.44 | -1.28 |
| Normalized Diluted EPS | -0.88 | -0.91 | -0.90 | -0.90 | -0.80 |
| Average Basic Shares Outstanding | 855.89M | 803.54M | 748.83M | 693.93M | 677.00M |
| Average Diluted Shares Outstanding | 855.89M | 803.54M | 748.83M | 693.93M | 677.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |